Outcomes in Solid-Organ Transplant Recipients After the First Dose of Either SARS-CoV-2 mRNA Vaccine

While no safety issues arose, only 17% of transplant recipients developed detectable antibodies to the SARS-CoV-2 spike protein.

Because immunosuppressed individuals have been largely excluded from SARS-CoV-2 vaccine trials, little is known about vaccine safety and efficacy in this population. In two studies, investigators report serologic responses and safety in solid-organ transplant (SOT) recipients (median time from transplant, 6 years) after receiving one dose of either mRNA vaccine.

Blood samples from 436 SOT recipients were tested for SARS-CoV-2 antibodies after receipt of the Pfizer-BioNTech (52%) or Moderna (48%) mRNA vaccine. Anti-spike antibody was detected in 17% of participants at a median 20 days postvaccination. Seropositivity was less likely in those who were older, were on an antimetabolite, or received the Pfizer-BioNTech vaccine. In 187 participants…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Outcomes in Solid-Organ Transplant Recipients After the First Dose of Either SARS-CoV-2 mRNA Vaccine

Topics

Reviewing Author